HBM Healthcare Investments' portfolio company Swixx BioPharma boosts sales
and profits through strategic acquisition in Latin America

HBM Healthcare Investments AG / Key word(s): Acquisition
HBM Healthcare Investments' portfolio company Swixx BioPharma boosts sales
and profits through strategic acquisition in Latin America

22.05.2024 / 18:17 CET/CEST

---------------------------------------------------------------------------

Swixx BioPharma, the largest investment in the private equity portfolio of
HBM Healthcare Investments, today announced its strategic expansion into
Latin America with the signing of an agreement to acquire the Laboratorios
Biopas Group.

The acquisition of Biopas builds on Swixx BioPharma's rapid rate of organic
growth and extends & transforms the company's footprint. With USD 220
million in sales, over 300 employees and therapeutic coverage in Neurology,
Oncology, Gastroenterology and Rare Diseases, Biopas is one of Latin
America's leading independent marketing and distribution companies for
international biopharmaceutical firms. Biopas has its operational
headquarters in Bogota, Colombia and is present in 20 countries, including
Latam's "Top 5" markets of Argentina, Brazil, Chile, Colombia & Mexico.

The acquisition of Biopas follows on the entry of Swixx BioPharma into the
Middle East region in September 2023 and marks another important step toward
Swixx's mission to become the global partner of choice for biopharma
companies seeking indirect routes to launch their medicines. Through Biopas'
comprehensive Latam continental coverage, Swixx will now be able to provide
a compelling offering covering Central and Eastern Europe, CIS/Eurasia, MENA
and now Latin America.

Swixx BioPharma expects the transaction to be immediately accretive. The
company will finance the acquisition through a combination of cash held on
its balance sheet, bank loans and equity. Closing of the transaction is
expected after relevant regulatory approvals, anticipated around mid 2024.
HBM Healthcare Investments has been a significant shareholder in Swixx
BioPharma since 2017, with a stake of approximately 25 per cent.

About Swixx BioPharma AG

Swixx BioPharma operates fully owned subsidiaries across Central and Eastern
Europe, Greece, Russia and several Eurasian countries including Belarus,
Kazakhstan, Uzbekistan, the Middle East and now Latin America. Swixx
BioPharma has over 1,300 employees and sales likely to exceed a billion
Euros in 2024. The company is one of the fastest-growing, largest,
independent, intercontinental commercial platforms for the biopharmaceutical
industry. Swixx has gathered outstanding rare disease, oncology-hematology,
specialty, vaccines and self-medication talent under one roof. For more
information about Swixx BioPharma, please visit: www.swixxbiopharma.com.

About Laboratorios Biopas Group

Biopas is a leading pharmaceutical company in Latin America, specializing in
the in-licensing, marketing, and sale of cutting-edge specialty
pharmaceutical products. Our mission is to address unmet medical needs and
facilitate access to innovative medicines. We provide efficient solutions to
international pharmaceutical companies seeking to tap into sales
opportunities across the region. Operating throughout Latin America with
fully owned subsidiaries, we hold leading positions in CNS, Immunology,
Dermatology, Gastroenterology, Oncology, and Rare Disease
biopharmaceuticals. Our anticipated sales for 2024 are approximately USD 220
million, supported by a dedicated team of over 300 employees.

Contact
For further information, please contact Dr Andreas Wicki on +41 41 710 75
77, or at andreas.wicki@hbmhealthcare.com.


---------------------------------------------------------------------------

End of Media Release

---------------------------------------------------------------------------

   Language:       English
   Company:        HBM Healthcare Investments AG
                   Bundesplatz 1
                   6300 Zug
                   Switzerland
   Phone:          +41438887171
   Fax:            +41438887172
   E-mail:         info@hbmhealthcare.com
   Internet:       https://www.hbmhealthcare.com
   ISIN:           CH0012627250
   Valor:          1262725
   Listed:         SIX Swiss Exchange
   EQS News ID:    1909139

End of News EQS News Service
---------------------------------------------------------------------------

1909139 22.05.2024 CET/CEST